Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650PUBT·2 days ago, 08:10 PMVRXA-1.43%
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phasebusinessinsider·Aug 25 at 03:01 PMVRXA-1.43%
VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precisionbusinessinsider·Aug 24 at 05:11 PMVRXA-1.43%
Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with SecarnaPUBT·Aug 24 at 11:39 AMVRXA-1.43%
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) AllianceUnusual Whales·Aug 24 at 11:02 AMVRXA-1.43%
Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platformsPUBT·Jul 31 at 08:06 PMVRXA-1.43%
Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestonePUBT·Jul 27 at 08:17 PMVRXA-1.43%OABI+13.51%
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbUnusual Whales·Jul 27 at 11:02 AMVRXA-1.43%OABI+13.51%
Veraxa Biotech shareholders approved all proposals at extraordinary general meetingPUBT·Jul 24 at 08:05 PMVRXA-1.43%
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth | VRXA Stock NewsStockTitan·Jul 24 at 12:05 PMVRXA-1.43%
Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick AustinPUBT·Jul 23 at 11:02 AMVRXA-1.43%
Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development planPUBT·Jul 20 at 11:01 AMVRXA-1.43%
